HNSCC Clinical Trial
Official title:
Using Whole-Genome Analysis on Cancer Tissue of Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
To choose a subgroup who could clearly benefit from Nivolumab, we are proposing a prospective observational study. Whole-genome study (WGS) analysis will be performed on archived cancer tissues from patients who were (1) cisplatin-refractory and subsequently (2) received Nivolumab (at least 4 doses) and (3) had completed imaging response evaluation at 3-4 month after Nivolumab. The estimated sample size was designed to be 80, including 20 responders and 60 non-responders (1:3 design) after Nivolumab alone at a dosage of 2-3mg/kg every 2 weeks (+/- 7 days could be allowed), given the minimal requirement of statistical significance. The specific bio-signature(s) found in this prospective observational study could possibly greatly contribute to precision immuno-oncology medicine, especially Nivolumab.
1-1 PD-1 pathway as a novel and effective pathway in cancer treatment The programmed death 1
(PD-1) receptor, which is expressed on activated T cells, is engaged by ligands PD-L1 and
PD-L2, which are expressed by tumor cells and infiltrating immune cells 1. Tumor PD-L1
expression is commonly seen in a broad spectrum of cancers, and the interaction between PD-1
and PD-L1, PD-L2 ligands inhibits T-cell activation and promotes tumor immune escape (i.e.,
the mechanism by which tumor cells escape recognition and elimination by the immune system)
2, 3. Immune checkpoint inhibitors (ICI) developed on the basis of the above mechanism have
shown their success with good treatment efficacy in patients with melanoma4-8, lung cancer3,
7, 9-21, and renal cell carcinoma12, 22-24 to date. Owing to the mechanism of targeting
probably very common pathways of cancer (PD-1 pathway), ICIs seems to be equally effective in
a wide range of cancers with a similar response rate of 20-30% 25, which indicates a common
immune defect on PD-1 pathway exists amongst the various type of cancer.
1-2 Subpopulation selection could possibly contribute better efficacy Recently, two PD1
inhibitors, Nivolumab and Pembrolizumab, showed their different results in large-scale
clinical trials 11, 14. Subpopulation selection strategies in these 2 trials have been widely
considered as one of the major reasons. A precise selection of patients with the best
response is critically warranted and a truly unmet need, given PD-L1 cannot clearly stratify
patients who will benefit most from Nivolumab.
1-3 No available biomarkers to predict severe irAEs is an unmet need Another problem is that
all ICIs have occasionally severe and sometimes life-threatening immune-related adverse
events (irAEs). At present, no good biomarker is available to predict such irAEs. It is
imperative to identify the biomarkers that can predict the risk of severe irAEs 25.
1-4 NGS technology could probably provide solutions to the above 2 problems Next-generation
sequencing (NGS) technology has been introduced in recent years (Fig. 1), and allows the
analysis of genomes, including those representing disease states 26, 27. Generally speaking,
there are three NGS approaches to improve diagnostics for cancer gene mutations: (1) targeted
enrichment of a set of genes (gene panel), (2) whole-exome sequencing (WES), and (3)
whole-genome sequencing (WGS) 28. When comparing the three options, it is clear
that—theoretically—WGS is the superior approach as it will produce the most complete data set
on an individual's genome (Table 1)28. A recent study 29 concluded that WGS offers significant
advantages of (a) more coverage of the exome, (b) detection of intronic variants, and (c)
calling of all structural variants, including single exon deletions; however, the costs and
testing time limited the routine use of WGS. In brief, WGS for cancer patients before
treatment could most possibly help to select patients with specific signature(s) to receive
specific treatment in a manner of precision medicine 30-37.
1-5 Host immunity (inherent, host) and Cancer (somatic, acquired) interaction could only be
seen in whole genome analysis By means of WGS, we could approach the question of how to
identify the responders from Nivolumab in the direction of "cancer part (somatic)"
conventionally. In another way, we could also approach this question by "host part", which is
also the advantages of WGS testing.
In WGS analysis, we could use genome-wide association studies (GWAS) analysis to compare
common genetic variants in large numbers of affected cases to those in unaffected controls to
determine whether an association with disease exists 38, 39. GWAS have been made possible by
the identification of millions of single nucleotide polymorphisms (SNPs) across the human
genome and the realization that a subset of these SNPs can capture ("tag") common genetic
variation via linkage disequilibrium 40. By SNP analysis in WGS, we proposed to find
genotypic characteristics to predict which patients could more possibly respond to Nivolumab.
In further hypothesis, we could analyze the upstream and downstream of the B cell signaling
pathway in addition to T cell pathway. Currently, almost all studies addressed the T
functional analysis when investigating PD-1-PD-L1 inhibitors. We hypothesize that B cell or
even Natural killer's pathway could play some roles to T cell activation to help us to
predict the response of immunotherapy.
1-6 Current evidence of NGS for stratification before ICIs Currently, there are only very few
data available carrying out a design using the WGS method. In 2016, Kimura et al. 25 from the
U.S.A used targeted panel NGS to prove a strong T cell response and further suggested to
exclude of patients with subclinical autoimmune disease is very important for treatment with
immune checkpoint inhibitors 25. Yaghmour et al. (2016) also used a panel NGS (Foundation One
panel) and found that the use of immune checkpoint blockade in tumors with higher mutational
load was associated with improved OS. They further suggested that the evaluation of tumor
genomes may be predictive of immunotherapy benefit 41. Voss et al. (2016) presented their
preliminary data using WES and RNA-Seq in patients with RCC in ASCO. They found that somatic
mutations, particularly those causing tumor neoantigens, and the counterbalance between
molecular immune compartments may be determinants of treatment benefit from Nivolumab and
warrant future study 42. Another team (de Velasco et al.) also found that both DNA- and
RNA-level data may be relevant for explaining clinical benefit from nivolumab in mRCC. In
contrast with results from other tumor types, responders to nivolumab did not have more
mutated tumors, though immune-related gene expression may be related to response 43. However,
their sample sizes of study, retrospective in nature, study scale, and NGS methods are all
relatively small.
Fig. 1. Recent advances of genetic analysis.44
Fig 2. The differences between several methods of NGS analysis. 45
1-7 The purpose of the study and brief design To choose a subgroup who could clearly benefit
from Nivolumab, we are proposing a prospective observational study. Whole-genome study (WGS)
analysis will be performed on archived cancer tissues from patients who were (1)
cisplatin-refractory and subsequently (2) received Nivolumab (at least 4 doses) and (3) had
completed imaging response evaluation at 3-4 month after Nivolumab. The estimated sample size
was designed to be 80, including 20 responders and 60 non-responders (1:3 design) after
Nivolumab alone at a dosage of 2-3mg/kg every 2 weeks (+/- 7 days could be allowed), given
the minimal requirement of statistical significance. The specific bio-signature(s) found in
this prospective observational study could possibly greatly contribute to precision
immuno-oncology medicine, especially Nivolumab.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Recruiting |
NCT04370587 -
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04114136 -
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT02999087 -
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
|
Phase 3 | |
Recruiting |
NCT05877430 -
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT06446570 -
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
|
Phase 2 | |
Completed |
NCT03292250 -
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
|
Phase 2 | |
Recruiting |
NCT05980000 -
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05581004 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04606940 -
Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
|
||
Recruiting |
NCT03356587 -
A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT04272333 -
Intratumoral Microdosing of Motolimod in HNSCC
|
Early Phase 1 | |
Completed |
NCT03367780 -
Dose-Effect Relation of Salivary Gland Irradiation
|
||
Recruiting |
NCT04141449 -
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
|
Phase 2 | |
Recruiting |
NCT04157985 -
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
|
Phase 3 | |
Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
Recruiting |
NCT05814666 -
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
|
Phase 2 | |
Recruiting |
NCT04279509 -
Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE)
|
N/A | |
Recruiting |
NCT03526835 -
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT06090318 -
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
|
Phase 1/Phase 2 |